Peptides · Peptide comparison
Macimorelin vs MK-677 (Ibutamoren)
FDA-approved diagnostic test for adult growth hormone deficiency
The oral growth hormone secretagogue that tricks your body into producing more GH — no needles required.
- Growth Hormone
- Growth Hormone
At a glance
Quick comparison
Efficacy
Benefit ratings
Diagnostic Accuracy
Safety & Tolerability
Convenience & Patient Experience
Muscle and body composition
Recovery and athletic performance
Sleep quality and metabolic health
Technical data
Compound specifications
Macimorelin
- Molecular formula
- C26H30N6O3
- Molecular weight
- 474.6 g/mol
- Half-life
- 4.1 hours
- Bioavailability
- Oral; a liquid meal lowers Cmax by 55% and AUC by 49%, so it is given after at least an 8-hour fast
- CAS number
- 381231-18-1
MK-677 (Ibutamoren)
- Molecular formula
- C27H36N4O5S
- Molecular weight
- 528.7 g/mol
- Half-life
- 4-6 hours (IGF-1 elevation persists ~24 hours)
- Bioavailability
- High oral bioavailability
- CAS number
- 159634-47-6
Protocols
Dosing compared
Macimorelin
Oral
- 0.5 mg/kgSingle dose · One-time diagnostic testFDA-label (Macrilen) single oral dose for diagnosing adult growth hormone deficiency. Granules (60 mg) are reconstituted in 120 mL water (0.5 mg/mL) and taken after an 8-hour fast; serum GH below 2.8 ng/mL across the 30/45/60/90-minute draws confirms deficiency [4].
MK-677 (Ibutamoren)
Oral
- Weeks 2-410 mgOnce daily · 2-4 weeks initialLower entry dose used in practice to limit water retention and appetite surge before titrating up.
- Studied up to 1-2 years25 mgOnce daily · Studied up to 1-2 years25 mg once-daily oral is the dose used in the randomized trial in healthy older adults; increased GH/IGF-1 and fat-free mass [1]. Most-studied dose [2].
Applications
Best suited for
Macimorelin
- Diagnosis of Adult Growth Hormone Deficiency
- Macimorelin is FDA-approved specifically for diagnosing AGHD in adults. It replaces the insulin tolerance test (ITT) as a safer, more convenient, and equally accurate diagnostic option. Phase 3 trials showed 87% sensitivity and 96% specificity.
- Patients Intolerant or Contraindicated for ITT
- For patients who cannot safely undergo insulin tolerance testing due to cardiac risk, seizure history, or other contraindications, macimorelin offers an evidence-based non-invasive alternative.
- Clinical Confirmation Testing
- Retesting agreed with the first result in 97% of people in the published trial. [1] It is a diagnostic test only: GH therapy must be stopped at least one week before testing, so it cannot be used to monitor treatment. [5]
MK-677 (Ibutamoren)
- Older Adults (60+) Seeking Body Composition Improvements
- MK-677 was designed for aging populations. It restores GH and IGF-1 to youthful levels, [7] increases lean mass, and improves physical function in people over 60. A 2-year clinical trial showed a 1.1 kg gain in fat-free mass [1] with only modest fat gain—ideal for maintaining strength in older age.
- Athletes and Fitness Enthusiasts Wanting Recovery Support
- Oral dosing makes MK-677 convenient for athletes. It enhances muscle protein synthesis, speeds recovery after intense training, and supports lean mass building without the hassle of injections.
- People with Chronic Wasting or Protein Deficiency
- Clinical trials show MK-677 helps treat protein-energy wasting in kidney disease and other conditions. [2] It stimulates appetite (a feature in these populations) and preserves muscle tissue—making it useful for those losing mass despite good nutrition.
Safety profile
Side effects
Macimorelin
Common
- Dysgeusia (abnormal taste)
- Dizziness
- Headache
- Fatigue
- Nausea
- Increased Appetite
Serious
- Cardiovascular events
MK-677 (Ibutamoren)
Common
- Increased appetite
- Mild water retention or edema
- Elevated fasting glucose
Uncommon
- Joint or muscle pain
- Carpal tunnel syndrome or nerve compression symptoms
- Mild nausea or digestive upset
Serious
- Glucose dysregulation and diabetes risk
Research status
Safety & evidence
Macimorelin
- Evidence level
- Strong human trials (Phase 3 or FDA approved)
- FDA status
- FDA approved for this use
- Safety overview
- Macimorelin is given once, as a single oral dose for a diagnostic test. In the registration trial (154 people dosed), the most common reactions were taste disturbance (4.5%), dizziness, headache and fatigue (3.9% each), and nausea and hunger (3.2% each). [5] No serious adverse events were reported for macimorelin. [1] It raises the corrected QT interval by about 11 msec; QT prolongation can lead to torsade de pointes, so the label says to avoid drugs that prolong the QT interval. [5] The label lists no contraindications. [5]
Contraindications
- None — the FDA label lists no contraindications [5]
MK-677 (Ibutamoren)
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- MK-677 has been studied in hundreds of humans over 2+ years and is generally well tolerated. [1][3] Most side effects are mild and manageable, especially with lower starting doses. The lack of injection requirement makes it safer than injectable GH in terms of infection risk and sterility concerns. However, it is not FDA approved and should be viewed as a research compound.
Contraindications
- Uncontrolled diabetes or severe glucose dysregulation
- Active cancer or high cancer risk requiring caution with IGF-1 elevation
- Pregnancy or breastfeeding
Decision guide
Which is right for you?
Macimorelin
Choose Macimorelin if…
- Diagnosing adult growth hormone deficiency (AGHD)
- Patients who cannot tolerate or are contraindicated for insulin tolerance test
- Clinical settings requiring convenient, repeatable hormone testing
- Healthcare providers seeking FDA-approved diagnostic alternatives
MK-677 (Ibutamoren)
Choose MK-677 (Ibutamoren) if…
- Building lean muscle mass and strength
- Improving overall body composition in aging adults
- Enhancing athletic recovery and performance
- Supporting metabolic health and fat loss